COVID-19 Vaccination is Associated With Favorable Outcomes Among Lung Transplant Patients With Breakthrough...

Area of Science:

• Immunology
• Transplant Surgery
• Infectious Diseases

Background:

• Limited data exists on COVID-19 vaccine efficacy in lung transplant (LT) patients.
• Assessing vaccine effectiveness is crucial for this immunocompromised population.

Purpose of the Study:

• To evaluate the clinical outcomes of COVID-19 breakthrough infections in lung transplant recipients based on vaccination status.
• To determine the impact of vaccination and booster doses on disease severity and survival.

Main Methods:

• Retrospective analysis of 84 lung transplant patients diagnosed with COVID-19 between March 2020 and December 2021.
• Patients categorized into unvaccinated, vaccinated (primary series), and boosted groups.
• Outcomes assessed included pulmonary involvement, respiratory failure, and oxygen-dependence-free survival.

Main Results:

• Boosted patients showed less pulmonary parenchymal involvement on CT scans (P=.009).
• Vaccinated and boosted groups had significantly lower rates of new or worsening respiratory failure.
• Vaccination and booster doses were associated with improved oxygen-dependence-free survival (P=.02).

Conclusions:

• COVID-19 vaccines demonstrate favorable effects in lung transplant patients experiencing breakthrough infections.
• Vaccination, particularly with a booster, is linked to reduced allograft involvement, hospitalization, and respiratory failure.
• Therapeutic anticoagulation and booster doses showed a protective effect against respiratory failure.